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M A J O R A R T I C L E
Microarray Detection of Human Parainfluenzavirus
4 Infection Associated with Respiratory Failure
in an Immunocompetent Adult
Charles Y. Chiu,1,3,a Silvi Rouskin,1,a Anita Koshy,7,a Anatoly Urisman,1 Kael Fischer,1 Shigeo Yagi,8 David Schnurr,8
Paul B. Eckburg,7 Lucy S. Tompkins,7 Brian G. Blackburn,7 Jason D. Merker,6 Bruce K. Patterson,6,7 Don Ganem,2,3,4,5
and Joseph L. DeRisi1,4,5
Departments of 1Biochemistry and Biophysics, 2Microbiology, 3Infectious Diseases, and 4Medicine and 5Howard Hughes Medical Institute,
University of California, San Francisco, 6Department of Pathology and 7Division of Infectious Diseases and Geographic Medicine, Department
of Medicine, Stanford School of Medicine, Palo Alto, and 8Viral and Rickettsial Disease Laboratory, California Department of Health Services,
Richmond, California
A pan-viral DNA microarray, the Virochip (University of California, San Francisco), was used to detect human
parainfluenzavirus 4 (HPIV-4) infection in an immunocompetent adult presenting with a life-threatening acute
respiratory illness. The virus was identified in an endotracheal aspirate specimen, and the microarray results
were confirmed by specific polymerase chain reaction and serological analysis for HPIV-4. Conventional clinical
laboratory testing using an extensive panel of microbiological tests failed to yield a diagnosis. This case suggests
that the potential severity of disease caused by HPIV-4 in adults may be greater than previously appreciated
and illustrates the clinical utility of a microarray for broad-based viral pathogen screening.
Hospitalized patients who are admitted with unex-
plained critical respiratory illness have a high mortality
rate, often 130% [1]. In the Unexplained Deaths and
Critical Illnesses Project study from 1995–1998, a pu-
tative infectious agent was identified only 39% of the
time, despite extensive laboratory testing [1]. Thus,
there is a need for new approaches to the identification
of pathogens in this setting. Here, we describe a case
of human parainfluenzavirus type 4 (HPIV-4) infection
in an immunocompetent adult who presented with rap-
idly progressive respiratory failure. Extensive conven-
tional microbiological testing for infectious agents was
unrevealing. The causative pathogen was finally iden-
tified in a sample of endotracheal aspirate using the
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Virochip (University of California, San Francisco), a
pan-viral DNA microarray that is designed to detect
both known and novel viruses on the basis of sequence
homology [2, 3]. To our knowledge, this is the first
report of respiratory failure from HPIV-4 in a healthy,
immunocompetent adult.
CASE REPORT
A previously healthy 28-year-old woman presented to
Stanford University Medical Center (Palo Alto, CA) in
December 2005 with a 10-day history of fever, pro-
ductive cough with hemoptysis, night sweats, and my-
algia. Three days prior to admission, she was treated
as an outpatient with oral azithromycin for presumptive
community-acquired pneumonia, but her symptoms
worsened despite treatment. The patient lived in Nor-
way prior to moving to California in October 2005. She
was a laboratory researcher but denied occupational
exposure to infectious agents. She had 2 pet cats and
was a cigarette smoker. A coworker had also recently
been ill with a respiratory tract infection.
At admission, the patient had a temperature of 39C
and a resting oxygen saturation of 96% that decreased
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Figure 1. Imaging and lung pathology from the patient. A chest radiograph (A) obtained at admission revealed bilateral reticulonodular infiltrates
with associated lower lobe consolidations, whereas a CT scan (representative slice; B) showed bilateral centrilobular nodules with a tree-in-bud
appearance suggestive of bronchiolitis. After intubation, a chest radiograph was performed on the patient on hospital day 4 that revealed persistent
bilateral infiltrates (C). On day 7 after hospital admission, findings from lung biopsy analysis revealed an organizing bronchiolitis but no direct histological
evidence of virus infection (hematoxylin and eosin stain, low magnification; D).
to 80% with any movement. Her leukocyte count was 21,000
cells/mm3, with 87% neutrophils. A chest radiograph revealed
bilateral reticulonodular infiltrates (figure 1A), and a CT an-
giogram revealed diffuse bronchiolitis (figure 1B). The patient
was treated with ceftriaxone and doxycycline and was placed
in respiratory droplet isolation. The results of initial laboratory
tests, including blood and sputum cultures, rheumatoid factor,
and antinuclear antibody, were negative.
On day 3 after hospital admission, the patient underwent
bronchoscopy, which revealed mild edema and hyperemic
bronchioles. The results of an immunofluorescence test for
Pneumocystis jiroveci were negative, as were bacterial, fungal,
and acid-fast bacilli cultures of bronchoalveolar lavage fluid
samples. A shell vial assay for cytomegalovirus and cytomeg-
alovirus PCR of bronchoalveolar lavage fluid specimens also
yielded negative results. Direct fluorescent antibody testing of
bronchoalveolar lavage fluid using the D3TM-DFA Respiratory
Virus Screening and ID Kit (Diagnostic Hybrids) failed to detect
respiratory syncytial virus, adenovirus, influenzavirus A and B,
and parainfluenzavirus types 1, 2, and 3. Likewise, viral bron-
choalveolar lavage fluid culture using 2 rhesus monkey kidney
cell lines, 2 human fibroblast cell lines, and a continuous A549
human alveolar epithelial cell line failed to demonstrate cyto-
pathic effect or hemadsorption, despite incubation for 21 days.
After bronchoscopy, the patient became dependent on me-
chanical ventilation and pressors, and serial chest radiographs
revealed persistent bilateral infiltrates (figure 1C). Antimicrobial
therapy was changed to moxifloxacin and oseltamivir, and high-
dose methylprednisolone therapy was initiated. Results of viral
direct fluorescent antibody testing for the 7 respiratory viruses
and 14-day viral cultures performed on endotracheal aspirate
specimens obtained on days 3 and 4 after hospital admission
were negative. Nose swab viral cultures performed on day 5
were also negative.
On day 7 after hospital admission, given her critically ill
condition and persistent unexplained respiratory failure, the
patient underwent a diagnostic open-lung biopsy. Histopath-
ologic analysis revealed an organizing bronchiolitis without
granulomas, multinucleated giant cells, or viral nuclear inclu-
sions (figure 1D). The pathology was primarily bronchiolocen-
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tric, with the lumens of the bronchioles filled with granulation
tissue plugs and eosinophils. These features were not typical
for vasculitis, cryptogenic organizing pneumonia, or acute
bronchopneumonia.
The patient improved clinically with continued supportive
care, and by day 15 after hospital admission, she was weaned
off of mechanical ventilation. She was discharged on day 26
after hospital admission. Additional laboratory studies per-
formed during the course of the patient’s hospitalization failed
to identify the etiology of her illness. These studies included
PCR of brochoalveolar lavage fluid specimens for the severe
acute respiratory syndrome (SARS) coronavirus and for me-
tapneumovirus, as well as PCR and direct fluorescent antibody
testing of a nasopharyngeal specimen for Bordetella pertussis.
A urine test for Legionella antigen and a serum test for cryp-
tococcal antigen both yielded negative results. Results of se-
rological analyses for HIV infection, histoplasmosis, blasto-
mycosis, tularemia, sporotrichosis, Q fever, leptospirosis, and
Sin Nombre hantavirus infection were negative. Serum samples
were tested twice during the patient’s hospitalization for coc-
cidioidomycosis, Mycoplasma and Chlamydia antibodies, and
the results were also negative.
Ultimately, diagnosis was made by examination of an en-
dotracheal aspirate from hospital day 4 using the Virochip assay.
The findings on microarray indicated the presence of HPIV-4,
which was confirmed by subsequent specific PCR and sero-
logical analysis.
METHODS
Clinical specimen collection and microarray screening.
On day 4 after hospital admission, an endotracheal aspirate
specimen from the patient was collected in a sterile cup con-
taining a viral culture medium (MEM [Nissui Corporation])
and stored at 80C. The sample used in the study was ob-
tained according to protocols approved by Stanford University’s
Institutional Review Board. Total RNA obtained from 1 mL of
sample was extracted using RNA-Bee (IsoTex Diagnostics), re-
verse-transcribed to cDNA, amplified by a modified Round A/
B random PCR method, and hybridized to the Virochip as
previously described [2–4]. The Virochip was scanned with an
Axon 4000B scanner (Axon Instruments) and GenePix soft-
ware, version 3.0 (NCBI GEO, series GSE4191).
The third-generation Virochip used here (NCBI GEO, plat-
form GPL3429; ∼22,000 oligonucleotides) was designed using
all partial sequences and fully-sequenced genomes deposited in
the GenBank database as of June 2004 (∼277,000 sequences)
and is a major expansion of the previous second-generation
chip (∼11,000 oligonucleotides) [3], which was designed in
2002 using fully-sequenced reference genomes (∼1000 se-
quences). Importantly for this study, the new microarray design
incorporates partial sequence information from 16 paramy-
xoviridae species for which complete genomic sequences are
not available.
Microarray analysis was performed by ranking the highest
intensity viral oligonucleotides by z-score. The z-score for a
specific oligonucleotide is defined as the distance in SDs of the
oligonucleotide intensity from its median intensity across all
arrays in our database performed to date ( ).np 1083
Microarray confirmation with PCR and serological
analysis. Microarray evidence of HPIV-4 was confirmed by
PCR of amplified cDNA from the patient’s endotracheal as-
pirate followed by sequencing. Previously published primers
[5–8] were used to amplify segments of the HPIV-4 genome
corresponding to the nucleoprotein, phosphoprotein, and ma-
trix genes. New primer sets were also designed to amplify con-
served regions within the genes coding for the fusion protein
(RUBULA-F1: 5′-TTGCWGGDGTDGYKRTWGG-3′; RUB-
ULA-R1: 5′-TTTGCWGGDGTDGYKRTWGG-3′) and large
protein (PI2-F1: 5′-GAGTAATGAGCATGGTTCAAGGAG-3′;
PI2-R1: 5′-CAGGAAGCTTGAGTACATTCACCTA-3′). The
RUBULA-F1 and RUBULA-R1 degenerate primers were de-
rived from ClustalW sequence alignment of the fusion genes
from parainfluenza 4a, parainfluenza 4b, and mumps viruses,
whereas the PI2-F1 and PI2-R1 primers were derived from the
sequence of the HPIV-2 large protein gene. Each reaction con-
tained 5.0 mL of 10 PCR buffer (Invitrogen Corporation), 2.0
mL of 50 mmol/L MgCl2, 1.0 mL of 10 mmol/L deoxyribonu-
cleoside triphosphates, 1.0 mL of forward primer and 1.0 mL
of reverse primer (10 pmol/mL each), 1 mL of Platinum Taq
DNA polymerase (Invitrogen Corporation; 5 U/mL), and 5.0
mL of template cDNA. Cycling parameters were as follows: 5
min of initial denaturation at 94C followed by 40 cycles of
denaturation (30 s at 94C), annealing (45 s at 50C), and
elongation (60 s at 72C), with a final extension at 72C for 8
min. Appropriate positive and negative controls were included
with each reaction, and amplified PCR bands of the expected
size were sequenced on an ABI PRISM 3700 DNA Analyzer
(Applied Biosystems). Sequences were then compared with
HPIV-4 entries in the GenBank database using the BLAST al-
gorithm [9].
Specific serological analysis for HPIV-4 using an indirect
immunofluorescence assay was performed according to estab-
lished protocols as previously reported [10]. Slides prepared
from primary monkey kidney cells that were productively in-
fected with human parainfluenzavirus 4a were used for the
immunofluorescence assay.
Broad-range PCR of lung biopsy tissue. DNA was ex-
tracted from fresh-frozen lung tissue using the QIAamp DNA
Mini Kit (Qiagen). Broad-range bacterial 16S and fungal 18S
rDNA PCR was performed on extracted DNA using bacterial
primers 8F (5′-AGAGTTTGATCCTGGCTCAG-3′) and 806R
(5′-GGACTACCAGGGTATCTAAT-3′) and fungal primers
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Figure 2. Graphic representation of the human parainfluenzavirus 4
(HPIV-4) genome (A). The major viral proteins include the nucleocapsid
protein (NP), phosphoprotein (P), nonstructural V protein (V), matrix protein
(M), fusion protein (F), hemagglutinin-neuraminidase protein (HN), and
large protein (L). The locations of the 6 paramyxovirus oligonucleotides
used to detect HPIV-4 on the microarray are mapped onto the ∼15 kB
genome (B). The corresponding z-score for each oligonucleotide is indi-
cated in parentheses. Five regions of the HPIV-4 virus obtained from a
sample of the patient’s endotracheal aspirate were sequenced (a–e, black
areas), 4 of which are within previously sequenced regions of the genome
(gray areas; C). Below each sequenced region is its percentage of nu-
cleotide identity to the corresponding HPIV-4a sequence in the GenBank
database.
ITS1-F (5′-CTTGGTCATTTAGAGGAAGTAA-3′) and ITS1-4R
(5′-TCCTCCGCTTATTGATATGC-3′) [1, 11, 12]. Each reac-
tion contained 5.0 mL of 10 PCR buffer-II (Applied Biosys-
tems), 3.0 mL of 25 mmol/L MgCl2, 2.5 mL of 1% Triton X-
100, 4.0 mL of 250 mmol/L tetramethylammonium chloride,
2.0 mL of 10 mmol/L deoxyribonucleoside triphosphates, 1.0
mL of forward primer and 1.0 mL of reverse primer (20 pmol/
mL each), 0.5 mL of AmpliTaq DNA polymerase (Applied Bio-
systems; 5 U/mL), and 5.0 mL of template DNA. Cycling pa-
rameters were as follows: 5 min of initial denaturation at 95C,
followed by 35 cycles of denaturation (30 s at 95C), annealing
(30 s at 56C), and elongation (60 s at 72C), with a final
extension at 72C for 8 min. A mock extraction control was
included throughout the tissue lysis and PCR. Amplified prod-
ucts were verified by gel electrophoresis using 1.0% agarose
gels.
RESULTS
Because conventional diagnostic test results were negative, the
Virochip, a pan-viral DNA microarray, was used to screen for
a possible infectious agent. Traditional methods of microarray
analysis include visual inspection and hierarchical clustering
[13, 14]. Visual inspection involves examination of the viral
identities of the oligonucleotides with the highest intensities,
whereas hierarchical clustering uses a set of microarrays to
group oligonucleotides with similar intensity profiles to identify
patterns that may correspond to a particular virus. Neither
visual inspection nor hierarchical clustering detected a con-
vincing viral signature on the microarray. Thus, we used a new
data analysis method, the z-score metric, which has been im-
plemented in our laboratory for identifying weak viral signa-
tures. The z-score metric estimates the statistical significance
of individual oligonucleotides on the microarray. Manual in-
spection of the top 100 viral oligonucleotides ranked by z-score
revealed a possible paramyxovirus signature, because 6 para-
myxoviridae oligonucleotides were among the top 100 with z-
scores ranging from 2.21–3.71 (figure 2B, 1–6). Four of the
oligonucleotides were derived from human parainfluenzavirus
4a, 1 from human parainfluenzavirus 4b, and 1 from simian
parainfluenzavirus 5, a close relative of HPIV-4. The 6 oligo-
nucleotides mapped to 4 different regions in the HPIV-4 ge-
nome, corresponding to the nucleocapsid protein, phospho-
protein, fusion protein, and large protein (figure 2A and 2B).
The microarray finding of HPIV-4 was then confirmed by
PCR of amplified cDNA obtained from the patient’s endotra-
cheal aspirate specimen. PCR using primers directed to the
fusion gene of HPIV-4 yielded a 473–base pair fragment that
was sequenced and found to share 97% nucleotide identity and
99% amino acid identity with the corresponding region of
HPIV-4a in the GenBank database (figure 2C, d). HPIV-4 se-
quences from the nucleoprotein, phosphoprotein, matrix, and
large protein genes were also obtained by PCR (figure 2C, a–
e). All fragments shared over 92% nucleotide identity with
available HPIV-4 sequences in the GenBank database, including
99% nucleotide identity in the matrix protein—the most con-
served region of the HPIV-4 genome (figure 2C, c).
The diagnosis of HPIV-4 infection was confirmed by ex-
amining antibody titers from patient serum samples that were
collected on days 13, 23, 24, 31, and 51 after symptom onset,
using an indirect immunofluorescence assay (figures 3A and
3B). A specific antibody response against HPIV-4 was observed,
with an 8-fold increase in IgG from day 13 (1:128) to day 24
(1:1024). The HPIV-4–specific IgG titers remained elevated 17
weeks after symptom onset during the patient’s convalescent
phase. In contrast, the results of convalescent-phase serological
analysis for parainfluenzavirus types 1, 2, and 3 performed at
7 weeks were negative, with IgG antibody titers of !1:8 by
complement fixation. Broad-range PCR of extracted lung bi-
opsy DNA using universal bacterial and fungal primers was also
negative.
DISCUSSION
We report a case of HPIV-4 infection in a previously healthy
adult who presented with a life-threatening febrile respiratory
illness. The key to identifying HPIV-4 was examining a broader
range of viral pathogens than is typical of standard clinical
laboratories. The Virochip is particularly well-suited for this
purpose, because it allows the unbiased detection of genomes
from all known viral families in a single assay. Although the
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Figure 3. Detection of antibody to human parainfluenzavirus 4 (HPIV-4)
by indirect immunofluorescence. A, Plot of the patient’s serum HPIV-4
IgG antibody titers over time. The 5 successive time points correspond
to days 13, 23, 24, 31, and 51 after symptom onset, the pink background
outlines the period of hospitalization, and the asterisk designates the
time point corresponding to panel B. The cytoplasm of infected cells
(white arrows) stains green against a background of uninfected cells in
red (B).
Virochip is an experimental research tool, a potential appli-
cation of this new technology, as demonstrated here, is rapid
and comprehensive screening for putative viral pathogens in
the acute clinical setting.
Because the patient was already receiving antibiotics at the
time of admission, negative culture results did not rule out a
concomitant bacterial or fungal infection. However, our neg-
ative results from broad-range PCR of lung biopsy DNA using
universal bacterial and fungal primers argued against this pos-
sibility. Furthermore, the overall clinical picture of a virus-like
upper respiratory infection prodrome, bilateral reticulonodular
pulmonary infiltrates, bronchiolitis on bronchoscopy, and
steady disease progression despite administration of broad-
spectrum antibiotics is most consistent with severe viral bron-
chiolitis/pneumonitis, and not with bacterial pneumonia.
HPIV-4 was identified as a potential candidate pathogen by
microarray and subsequent PCR of an endotracheal aspirate
sample collected on day 4 after hospital admission. Longitu-
dinal studies in children suggest that human parainfluenzavi-
ruses can be shed from the oropharynx for as long as 3–4 weeks
[15]. Thus, it is not surprising that we were still able to detect
HPIV-4 from a specimen collected on day 4 after hospital ad-
mission (which corresponds to ∼14 days after symptom onset).
Nosocomial infection with HPIV-4 is a remote possibility, al-
though a study of patients who received a diagnosis of acute
viral pneumonia in the intensive care unit revealed that nearly
all of these illnesses (11 [92%] of 12) were community acquired
[16]. Moreover, the patient’s HPIV-4–specific IgG antibody ti-
ter was already elevated at 1:128 by day 3 after hospital ad-
mission, making a nosocomial infection with HPIV-4 extremely
unlikely. Despite extensive microbiological testing, no other
pathogen was identified in the patient’s case. The documented
seroconversion that accompanied the clinical infection provides
strong additional support that this virus is the etiologic agent
for the patient’s illness.
HPIV-4 has primarily been associated with mild upper re-
spiratory infections in children and adults. Although serological
evidence suggests that HPIV-4 may account for up to 3% of
all respiratory tract infections [17], the clinical significance of
HPIV-4 in immunocompetent individuals is unknown. Diag-
nosis of HPIV-4 infection is problematic because HPIV-4 is
difficult to isolate in viral cultures, and standard commercial
direct fluorescent antibody panels available in most clinical
virology laboratories include only HPIV-1, -2, and -3 [18]. In
rare instances, HPIV-4 has been shown to cause severe respi-
ratory disease in children [17–19] and immunocompromised
individuals [20], but hitherto, it has not been associated with
acute respiratory failure in healthy, young adults. This case
further expands the documented clinical spectrum of HPIV-4
infection and supports specific testing for HPIV-4 in individuals
with unexplained critical respiratory illness.
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